

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period November 1 - 30, 2024

Supplementary Exhibit & Answers

Part 7, Question a. (Were any payments made on prepetition debt?):

The Debtors obtained post-petition financing consistent with the Interim Order Approving Motion to Approve Debtor In Possession Financing [Docket No. 103] and the Final Order (I) Authorizing the Debtors to Obtain Postpetition Financing, (II) Authorizing the Debtors to Use Cash Collateral, (III) Granting Liens and Providing Superpriority Administrative Expense Claims, (IV) Granting Adequate Protection, (V) Modifying Automatic Stay, and (VI) Granting Related Relief [Docket No. 248].

Part 7, Question c. (Were any payments made to or on behalf of insiders?):

Payments made on behalf of insiders include only regular salary and compensation to the Debtors' CEO, CFO, General Counsel, and/or independent directors.

Part 7, Question g. (Was there any postpetition borrowing, other than trade credit?):

The Debtors obtained post-petition financing consistent with the *Interim Order Approving Motion to Approve Debtor In Possession Financing* [Docket No. 103].

In re: Vyair Medical, Inc., et al.

24-11217 (BLS)

Statement of Cash Receipts and Disbursements

November 1 - 30, 2024

Operating Receipts

Collections

Total Operating Receipts**Vyair
Medical, Inc.
(Consolidated)**

\$ 2,924,282

2,924,282**Operating Disbursements**

Trade Vendors

Payroll & Comissions

T&E Credit card

State and other taxes

Insurance

Customs Duty

Inter-company transfers

Total Operating Disbursements

(5,081,179)

(2,609,643)

(124,154)

(53,489)

(335,019)

(4,834)

(142,635)

(8,350,952)**Net Cash Flow from Operations****(5,426,670)****Non- Operating Receipts / (Disbursements)**

Other Non-Estate Receipts

Other Non-Estate Disbursements

Other Non-Operational

Total Non- Operating Receipts / (Disbursements)

300,000

(669,000)

53,242,194

53,542,194**Total Net Cash Flow****48,115,524****Restructuring Receipts/(Disbursements)**

DIP Draw

DIP Interest & Fees

Professional Fees

Sale Proceeds to Lenders Roll Up Loans

Sale Proceeds to First Lien Agent Fees

D&O, Critical Vendor, and Other Contingency

Total Restructuring Receipts/(Disbursements)

(26,250,000)

(2,565,000)

(2,764,413)

(13,435,000)

(1,463,162)

(133,750)

(46,611,325)**Liquidity****Book Cash Balance - Start****14,614,023**

Net Cash Flow (+/-)

835,199

Change in Outstanding ACH/Wire/Check Balance

77,457

Book Cash Balance - End**15,526,680**

In re: Vyaire Medical, Inc., et al.
24-11217 (BLS)
Balance Sheet
November 1 - 30, 2024

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	18	16	17	15	19	20	21	22	23	24	25	26	27	28
	Vyaire Medical, Inc.	Bird Products Corporation	Breathre US Holdings, Inc.	Breathre US Holdings LP	EME Medical, Inc.	Revolutionary Medical Devices, Inc.	SensorMedics Corporation	VIASYS Holdings Inc.	VM Finance Sub, LLC	Vyaire Company	Vyaire Finance B.V.	Vyaire Financial Holdings LLC	Vyaire Holding Company	Vyaire Medical 200, Inc.	Vyaire Medical 200, Inc.	Vyaire Medical 200, Inc.	Vyaire Medical 200, Inc.	Vyaire Medical 211, Inc.	Vyaire Medical BR LLC	Vyaire Medical Capital LLC	Vyaire Medical Consumables LLC	Vyaire Medical International LLC	Vyaire Medical LLC	Vyaire Medical Payroll LLC	Vyaire Receivables LLC	Vyaire Respiratory Diagnostics LLC	Vyaire TSR MedCo, LLC	Vyaire TSR Sub, LLC
Current Assets																												
Assets Held for Sale	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
Cash & Cash Equivalents	9,050,178		3,356,292								(23,400)				2,578,223	(10,634)		9,112,423										
Income Taxes - Current															0													
Intercompany AR	2,989,777,200		121,048,051								113,423,881	1,422,704,346	107,751	342,691,128	185,286,995	2,372,427		11,742,939				259		1,103,195,040	2,409,122,714			
Inventories, Net	(1,053)														(8)			(2,116,470)										
Other	80,070,038																	(34,134)										
Prepaid Expense - Net	2,211,648																	(2,170,101)										
Related Party Receivables	40,507																											
Restricted Cash	964,000																											
Trade Receivables - Net	6,766,446														(3,969,773)	0		(502,543)							(245)	(0)		
Total Current Assets	3,088,857,961		124,404,343								113,400,481	1,422,704,346	107,751	342,691,128	184,935,869	2,361,794		16,031,605				259		1,103,195,359	2,414,326,270			
Long Term Assets																												
Intercompany Asset - LT	1,015,539,109	(47,150,760)	160,000				173,847,784	18,621,997			4,753,683		1,204,029,413	40,957,152	56,542,340			191,749,446	80,066,929				125,982,033					
Investments in Lessee LT	-																											
Fixed Assets, Net	15,605,472																	30,588										
Goodwill	-																											
Intangible Assets - Net	-																											
Right of Use Asset	120,704											5,000,000																
Other LT Assets	(0)												0															
LT Deferred Taxes	-																											
Total Long Term Assets	1,013,265,285	(47,150,760)	160,000				173,847,784	18,621,997	5,000,000		4,753,683		1,204,029,413	40,957,152	56,542,340			196,266,478	80,066,929				125,982,033					

In re: Vyair Medical, Inc., et al.
24-11217 (BLS)
Income Statement
November 1 - 30, 2024

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	18	16	17	15	19	20	21	22	23	24	25	26	27	28
	Vyaire Medical, Inc.	Bird Products Corporation	Breathe US HoldCo, Inc.	Breathe US Holdings LP	EME Medical, Inc.	Revolutionary Medical Devices, Inc.	SensorMedics Corporation	VIASYS Holdings Inc.	VM Finance Sub, LLC	Vyaire Company	Vyaire Finance B.V.	Vyaire Financial Holdings LLC	Vyaire Holding Company	Vyaire Medical 202, Inc.	Vyaire Medical 203, Inc.	Vyaire Medical 205, Inc.	Vyaire Medical 206, Inc.	Vyaire Medical 211, Inc.	Vyaire Medical BR LLC	Vyaire Medical Capital LLC	Vyaire Medical Consumables LLC	Vyaire Medical International LLC	Vyaire Medical Payroll LLC	Vyaire Receivables LLC	Vyaire Respiratory Diagnostics LLC	Vyaire TSR MidCo, LLC	Vyaire TSR Sub, LLC	
Revenue																												
Third Party Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	(2,595)	\$ -	\$ -	660,289	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Intercompany Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Revenue																(2,595)	-	-	660,289	-	-	-	-	-	-	-	-	-
COGS																												
Standard COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41,181	-	-	-	-	-	-	-	-	-	
IC COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
DCOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,209	-	-	-	-	-	-	-	-	-	
Total COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48,390	-	-	-	-	-	-	-	-	-	
Operating Expenses																												
Salaries & Benefits	438,345	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	123,393	-	-	-	-	-	-	-	-	-	
Other Operating Expenses	26,992,474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,429	-	1,230,607	-	-	-	-	-	-	-	-	-	
Total Operating Expenses	27,430,818	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,429	-	1,354,000	-	-	-	-	-	-	-	-	-	
Non-Operating Expenses																												
Amortizations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Currency	(963,710)	-	-	-	-	-	-	-	-	-	(0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net Interest	2,621	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Non-recurring charges	157,759	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Other Income Expense	(423,027,283)	-	-	-	-	-	-	-	-	-	(111,905,675)	-	-	-	-	(2)	-	-	-	-	-	-	-	-	-	-	-	
Disposal of Business	(52,247,564)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Restructuring	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Non-Operating Expenses	(476,078,177)	-	-	-	-	-	-	-	-	-	(111,905,675)	-	-	-	-	(2)	-	-	-	-	-	-	-	-	-	-	-	
Net Income	\$ 448,647,358	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 111,905,675	\$ -	\$ -	\$ -	\$ -	(12,022)	\$ -	\$ -	(742,101)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period 11/1/2024 - 11/30/2024

Bank Reconciliations

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed before closing the books each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

/s/ David Barse
Signature of Authorized Individual

12/23/2024
Date

David Barse
Printed Name of Authorized Individual

Plan Administrator
Title of Authorized Individual